Articles with "krasg12c inhibitors" as a keyword



Photo by ospanali from unsplash

Abstract 430: Pemigatinib, an FGFR inhibitor, overcomes resistance to KRASG12C inhibitors in mesenchymal-like NSCLC tumors

Sign Up to like & get
recommendations!
Published in 2023 at "Cancer Research"

DOI: 10.1158/1538-7445.am2023-430

Abstract: KRAS is one of the most frequently mutated oncogenes. Clinical studies with recently developed covalent KRASG12C inhibitors have shown promising anticancer activity in patients with KRASG12C tumors (substitution of glycine to cysteine at amino acid… read more here.

Keywords: expression; mesenchymal like; krasg12c inhibitors; krasg12c ... See more keywords
Photo from wikipedia

Abstract B035: Targeting transcriptional elongation kinases prevents adaptation to KRASG12C inhibitors in both MAPK-dependent and -independent models of acquired resistance

Sign Up to like & get
recommendations!
Published in 2023 at "Molecular Cancer Research"

DOI: 10.1158/1557-3125.ras23-b035

Abstract: The development of covalent inhibitors targeting KRASG12C mutations offers a precision medicine approach to a large cohort of lung cancer patients previously lacking opportunities for targeted therapy. Despite promising initial responses ranging from disease control… read more here.

Keywords: acquired resistance; mapk dependent; krasg12c inhibitors; krasg12c ... See more keywords
Photo from wikipedia

A Breakthrough Brought about by Targeting KRASG12C: Nonconformity Is Punished

Sign Up to like & get
recommendations!
Published in 2022 at "Cancers"

DOI: 10.3390/cancers14020390

Abstract: Simple Summary KRAS is the most common oncogene in human cancers and has long been considered ‘‘undruggable’’—that is, until recently, when covalent inhibitors that selectively target KRASG12C substitution were developed. The satisfactory results of multicenter… read more here.

Keywords: inhibitor; therapy; krasg12c inhibitors; krasg12c ... See more keywords
Photo from wikipedia

TEAD Inhibitors Sensitize KRASG12C Inhibitors via Dual Cell Cycle Arrest in KRASG12C-Mutant NSCLC

Sign Up to like & get
recommendations!
Published in 2023 at "Pharmaceuticals"

DOI: 10.3390/ph16040553

Abstract: KRASG12C is one of the most common mutations detected in non-small cell lung cancer (NSCLC) patients, and it is a marker of poor prognosis. The first FDA-approved KRASG12C inhibitors, sotorasib and adagrasib, have been an… read more here.

Keywords: cell; krasg12c inhibitors; krasg12c; mutant nsclc ... See more keywords